The primary outcome is a reduction in migraine frequency and intensity after 12 weeks of treatment. Secondary outcomes include improvements in photosensitivity, retinal vessel changes, and blood biomarker concentrations related to vascular tone.
In women, gepants showed a statistically significant drug effect on pain freedom (PF) and freedom from the most bothersome symptom (MBS) after 2 hours, with effects ranging from 7.4% to 12.4%. In contrast, the drug effect in men was markedly lower, indicating a preferential response in women.
Significant reduction in headache frequency and related disability was observed 6 and 12 months after the therapy, with median headache days decreasing from 30 at baseline to 13 at 12 months, and PedMidas scores improving from 30 to 7.
Patients reported a mean improvement of 72% in headaches on the treated side, with 12 patients experiencing complete resolution of headaches post-surgery. Significant reductions in headache days, severity, and need for emergency care were also noted after TOS treatment.
Ayurveda interventions showed potential in reducing signs and symptoms of sinusitis compared to placebo, with combined Ayurveda therapy being statistically more beneficial in reducing nasal discharge and headache symptoms.